Article
Analysis of Copy Number Loss of the ErbB4 Receptor Tyrosine Kinase in Glioblastoma
2017-06-23
Abstract excerpt
<h4>ABSTRACT</h4> Current treatments for glioblastoma multiforme (GBM)—an aggressive form of brain cancer—are minimally effective and yield a median survival of 14.6 months and a two-year survival rate of 30%. Given the severity of GBM and the limitations of its treatment, there is a need for the discovery of novel drug targets for GBM and more personalized treatment approaches based on the characteristics of an...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d2eb516e-60da-5421-be60-5daf5b645f4e
- DOI
- 10.1101/154815
